Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Imfinzi fails to meet main goals in head and neck cancer study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 02:55am EST
A sign is seen at an AstraZeneca site in Macclesfield

(Reuters) - AstraZeneca Plc immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head and neck cancer, the London-listed drugmaker said on Friday.

The study, known as "EAGLE", did not improve overall survival compared with standard chemotherapy in patients with the hard-to-treat disease, the company said.

The results come after AstraZeneca warned last month that its immunotherapy treatment Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.

AstraZeneca has been seen as having a head start in the race for cancer treatments, and Imfinzi was aiming to be the new standard of care in treating early inoperable stage III lung cancer.

"While these results are disappointing, we remain committed to evaluating the potential of Imfinzi and other innovative medicines for patients with head and neck cancer," said Chief Medical Officer Sean Bohen.

The trial was conducted at 169 centres across 24 countries including the U.S., Europe, South America, Japan, Korea, Taiwan, Israel and Australia, AstraZeneca said.

(Reporting by Sangameswaran S and Noor Zainab Hussain in Bengaluru; Editing by Sai Sachin Ravikumar, Bernard Orr)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
02/14ASTRAZENECA : Up Over 9% After 4Q Revenue, Core EPS Beats -- Data Talk
DJ
02/14LONDON STOCK EXCHANGE : FTSE 100 squeezes out gains; ConvaTec drags midcaps
RE
02/14European shares give up three-month highs after shock U.S. data
RE
02/14LONDON MARKETS: London Stocks Cling To Gains; AstraZeneca Surges On Results
DJ
02/14ASTRAZENECA : Turns a Corner After a Decade of Struggles -- 3rd Update
DJ
02/14EUROPE MARKETS: Trade Optimism Helps European Stocks Shrug Off Growth Fears
DJ
02/14GLOBAL MARKETS LIVE : Google, Airbus, Volkswagen, Cisco…
02/14ASTRAZENECA : New cancer drugs, China give AstraZeneca welcome sales boost
RE
02/14ASTRAZENECA : Set for Growth in 2019 -- Earnings Review
DJ
02/14ASTRAZENECA : 4Q Earnings Snapshot
AQ
More news
Financials ($)
Sales 2019 23 493 M
EBIT 2019 6 206 M
Net income 2019 2 766 M
Debt 2019 14 611 M
Yield 2019 3,50%
P/E ratio 2019 36,52
P/E ratio 2020 25,54
EV / Sales 2019 4,87x
EV / Sales 2020 4,42x
Capitalization 99 756 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 82,0 $
Spread / Average Target 3,0%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA3.75%99 756
JOHNSON & JOHNSON5.68%363 918
PFIZER-2.86%247 080
ROCHE HOLDING LTD.12.82%235 233
NOVARTIS7.14%228 721
MERCK AND COMPANY3.70%206 054